avacincaptad pegol Izervay
Selected indexed studies
- Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. (Lancet, 2023) [PMID:37696275]
- C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. (Ophthalmology, 2021) [PMID:32882310]
- "Izervay (avacincaptad pegol): paving the way for vision preservation in geographic atrophy". (Ann Med Surg (Lond), 2024) [PMID:38694318]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Treatment of dry age-related macular degeneration: A review. (2023) pubmed
- C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. (2021) pubmed
- Avacincaptad Pegol. (2006) pubmed
- Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. (2023) pubmed
- Avacincaptad Pegol: First Approval. (2023) pubmed
- C5 inhibitor avacincaptad pegol treatment for geographic atrophy: A comprehensive review. (2024) pubmed
- Avacincaptad Pegol Sodium. (2023) pubmed
- Vision Loss Reduction with Avacincaptad Pegol for Geographic Atrophy: A 12-Month Post Hoc Analysis of the GATHER1 and GATHER2 Trials. (2024) pubmed
- "Izervay (avacincaptad pegol): paving the way for vision preservation in geographic atrophy". (2024) pubmed
- Avacincaptad pegol (Izervay) for geographic atrophy in age-related macular degeneration. (2024) pubmed